Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CLORAZEPATE DIPOTASSIUM

All products: not a benefit

Other products in the same Health Canada class (N05BA) — coverage varies; not interchangeable

  • Alprazolam (Xanax): general benefit, Not a benefit
  • Bromazepam (Lectopam): general benefit, Not a benefit
  • Chlordiazepoxide (Librium): general benefit, Not a benefit
  • Diazepam (Diazepam Injection USP): general benefit, Limited Use 481, Not a benefit
  • Lorazepam (Apo-Lorazepam): general benefit, Not a benefit
  • Oxazepam (Apo-Oxazepam): general benefit, Not a benefit

1 more in the class list below

Tranxene · DIN 00264938 · 3.75mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-08-01 — choose a marketed DIN from the same-category list.Discontinued 2003-08-01 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-08-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-08-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tranxene · DIN 00264938 Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01 Health Canada: Cancelled post market since 2003-08-01 · brand TRANXENE CAP 3.75MG · ATC N05BA05 CLORAZEPATE POTASSIUM · form Capsule · route Oral · ingredients CLORAZEPATE DIPOTASSIUM 3.75 MG · company Abbott laboratories, limited · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Tranxene: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1655 · Verify on the e-Formulary ↗ (DIN 00264938)

Source record
DIN 00264938: Tranxene Raw flags: notABenefit=Y, sec3=Y Item: 281608022; group id 485; item number 1237; lccId None; manufacturer id ABB Source form: Cap; strength: 3.75mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00264938 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1655
Interchangeable products
Clorazepate · DIN 00860689 · $0.1972
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00264938
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2003-08-01 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ALPRAZOLAM

· 12 products · General benefit (6), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 0.25mg, 0.5mg, 1mg, 2mg · Tab

BROMAZEPAM

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 1.5mg, 3mg, 6mg · Tab

CHLORDIAZEPOXIDE

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 25mg · Cap

DIAZEPAM

· 10 products · Limited Use, codes 481 (1), General benefit (6), Listed, not a benefit (3) · strengths: 5mg/mL, 10mg/2mL, 15mg/3mL, 2mg, 5mg, 10mg · Inj Sol (Preservative Free), Rect Gel-2x 5mg Pk, Rect Gel-2x10mg Pk, Rect Gel-2x15mg Pk, Tab

LORAZEPAM

· 12 products · General benefit (9), Listed, not a benefit (3) · strengths: 0.5mg, 1mg, 2mg · Tab

OXAZEPAM

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 10mg, 15mg, 30mg · Tab

HYDROXYZINE HCL

· 8 products · Listed, not a benefit · strengths: 10mg, 25mg, 50mg · Cap

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS CLORAZEPATE (clorazepate dipotassium) is indicated for:  the short-term symptomatic relief of excessive anxiety and tension in psychoneurotic patients including those with functional somatic complaints.  the adjunctive management of acute alcohol withdrawal. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. See 4.2 Recommended Dose and Dosage Adjustment; 7.1.4 Geriatrics. Long-term use of CLORAZEPATE should be avoided in elderly patients. Enhanced monitoring is recommended. See 7 WARNINGS AND PRECAUTIONS, Falls and fractures; 4.1 Dosing considerations. https://pdf.hres.ca/dpd_pm/00064007.PDF PM date: DEC 31, 1990 Source product: CLORAZEPATE; DIN 00860689; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Tranxene: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026